Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the European Union Drugs Agency (EUDA).
Country |
Not used in the past month/occasional |
Once a week or less |
2 - 6 times per week |
Daily |
Base |
Status unknown |
|---|---|---|---|---|---|---|
Czech Republic |
0.0 |
23.1 |
0.0 |
76.9 |
13 |
4 |
Denmark |
0.0 |
0.0 |
25.0 |
75.0 |
24 |
7 |
Germany |
86.4 |
3.2 |
3.3 |
7.0 |
3985 |
0 |
Greece |
21.4 |
21.4 |
7.1 |
50.0 |
14 |
0 |
Cyprus |
0.0 |
0.0 |
50.0 |
50.0 |
2 |
0 |
Latvia |
0.0 |
0.0 |
18.2 |
81.8 |
11 |
4 |
Netherlands |
4.8 |
1.0 |
1.0 |
93.3 |
104 |
10 |
Slovenia |
0.0 |
0.0 |
0.0 |
100.0 |
1 |
0 |
Slovakia |
0.0 |
12.5 |
12.5 |
75.0 |
8 |
1 |
Finland |
3.3 |
6.7 |
20.0 |
70.0 |
30 |
0 |
Sweden |
5.2 |
5.2 |
6.5 |
83.1 |
77 |
0 |
Bulgaria |
20.0 |
20.0 |
0.0 |
60.0 |
5 |
0 |
Total |
80.9 |
3.3 |
3.6 |
12.1 |
4274 |
26 |
Notes: Only countries where there are clients reported with hypnotics and sedatives as primary drug are shown. Source: 2004 Reitox national reports - TDI - outpatient treatment centres – see [Table TDI-17] | ||||||